Drake et al 38 just published positive results of the first randomised trial ( NCT01074554 ) of an antimicrobial regimen (directed at atypical mycobacteria) in the USA using oral concomitant levofloxacin, ethambutol, azithromycin and rifampin (CLEAR) regimen to treat 30 patients with cutaneous sarcoidosis, with quite significant reductions in cutaneous lesion size.
← all excerpts
Molecular analysis of sarcoidosis lymph nodes for microorganisms: a case-control study with clinical correlates.
1
—
—